Business Context and Reporting Period
Company: Intellia Therapeutics, Inc. (NTLA)
Filing Type: Form 8-K (Current Report)
Date of Report: October 29, 2025
Event: Notification of a clinical hold by the U.S. Food and Drug Administration (FDA) regarding the Company's lead product candidate, nexiguran ziclumeran ("nex-z").
Key Financial Metrics
This filing is a Current Report (Form 8-K) detailing a specific regulatory event. It does not contain financial statements, revenue figures, profit data, cash flow metrics, debt levels, or liquidity information. The filing text does not provide a clear value for any financial metric.
Material Changes and Events
- FDA Clinical Hold: On October 29, 2025, the FDA verbally informed Intellia that it has placed a clinical hold on the Investigational New Drug (IND) applications for the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials for nex-z.
- Cause of Hold: The hold follows a previously disclosed report of Grade 4 liver transaminases and increased total bilirubin in a patient dosed with nex-z in the MAGNITUDE trial.
- Operational Status: The Company had already temporarily paused dosing and screening in these trials on October 27, 2025, based on protocol-defined pausing criteria.
- Next Steps: The FDA indicated it would provide a formal Clinical Hold Letter within 30 calendar days. Intellia intends to work with the FDA to resolve the hold expeditiously.
Guidance, Outlook, and Risks
Management Commentary: Management states an intention to resolve the clinical hold as quickly as possible but acknowledges significant uncertainty regarding the timeline and the specific actions or studies required to do so.
Forward-Looking Risks: The filing highlights several critical uncertainties, including:
- Uncertainty regarding when the clinical hold may be resolved.
- Implications of the hold on the safety, efficacy, and further development of nex-z.
- The risk that the MAGNITUDE and MAGNITUDE-2 trials may not be resumed or successfully completed.
- Broader risks related to regulatory approvals, intellectual property, and reliance on collaborations (specifically with Regeneron Pharmaceuticals, Inc.).
Investor Verification Checklist
- Monitor for the formal Clinical Hold Letter from the FDA, expected within 30 days of October 29, 2025.
- Review the specific safety data regarding the patient with Grade 4 liver transaminases and increased total bilirubin.
- Assess the potential impact of the clinical hold on the projected timeline for nex-z commercialization.
- Verify the status of the collaboration with Regeneron Pharmaceuticals, Inc., as the filing notes risks related to the continuation of this partnership.
- Check subsequent filings for updates on the resolution of the hold and any changes to the clinical trial protocols.